bioAffinity Technologies Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 2835 http://www.bioaffinitytech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies Inc

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research - Jan 24th, 2023 1:00 pm
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments - Jan 4th, 2023 1:00 pm
Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) - Dec 19th, 2022 4:33 pm
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench - Dec 15th, 2022 1:30 pm
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting - Dec 1st, 2022 1:00 pm
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 14th, 2022 12:30 pm
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board - Nov 10th, 2022 1:15 pm
bioAffinity Technologies to Report Third Quarter 2022 Financial Results - Nov 8th, 2022 1:00 pm
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia - Oct 25th, 2022 1:15 pm
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference - Oct 12th, 2022 12:15 pm
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M - Sep 28th, 2022 12:15 pm
bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE - Sep 14th, 2022 12:15 pm
WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering - Sep 6th, 2022 5:54 pm
bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering - Sep 6th, 2022 3:28 pm
WallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit - Sep 1st, 2022 4:32 pm
bioAffinity Technologies Announces Pricing of IPO - Sep 1st, 2022 12:15 pm